Chemours (CC) News Today

The Chemours Company (CC) — shares are trading down today following mixed Q1 results, updated guidance and fresh investor and regulatory concerns. Below are the key items investors should care about and why they may be moving the stock.

• Positive Sentiment: Q1 EPS beat consensus and management pointed to pricing gains that supported EBITDA, showing operational leverage despite volume weakness. The Chemours Company Reports First Quarter Results
• Positive Sentiment: Management gave Q2 adjusted EBITDA guidance of $220M–$250M and reiterated a target to bring net leverage below ~3.8x by year-end 2026 — guidance that supports cash flow improvement and deleveraging expectations. Chemours expects Q2 adjusted EBITDA of $220M-$250M
• Positive Sentiment: The board declared a quarterly cash dividend of $0.0875/share (ex-dividend May 15), which supports income-focused holders and signals confidence in near-term cash generation. Chemours Announces Second Quarter Dividend
• Neutral Sentiment: Revenue missed consensus (Q1 revenue ~$1.38B vs. ~$1.40B expected) and volumes were weaker in key segments, offset by pricing — a mixed beat that leaves near-term growth uncertain. Chemours' Q1 Earnings Surpass Estimates, Revenues Miss
• Neutral Sentiment: Company published the full Q1 earnings/earnings call transcripts and slide deck for detail — useful for investors parsing segment trends, margin drivers and working capital assumptions. Chemours (CC) Q1 2026 Earnings Transcript
• Negative Sentiment: Alta Fundamental sold ~175,000 Chemours shares in Q1 — an institutional reduction that can weigh on sentiment when combined with other outflows. Alta Fundamental Dumps 175K Chemours Shares in Q1
• Negative Sentiment: Rising PFAS regulatory risk and uncertain environmental liabilities in the U.S. and EU were highlighted by analysts/regulatory trackers — a material long-term liability that increases legal and compliance risk premium for the stock. Chemours Faces Rising PFAS Regulatory Risks
• Negative Sentiment: Some market commentary and research note pieces framed the stock decline and highlighted the Q1 operating deterioration (volumes) and headline losses, which likely amplified selling pressure today. Why The Chemours Company’s (CC) Stock Is Down 15.30%